About The Study: From 2020 to 2025, prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal and out-of-pocket costs rose substantially in 2025, as plans increasingly required coinsurance. Although the rise in prior authorization may reflect efforts to curtail off-label GLP-1RA use, recent increases in out-of-pocket costs likely resulted from broader shifts to coinsurance affecting many high-cost drugs.
Corresponding Author: To contact the corresponding author, Matthew J. Klebanoff, MD, MSHP, email matthew.klebanoff@pennmedicine.upenn.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.15841)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15841?guestAccessKey=90ed03f8-3941-432a-93c7-40f38610b943&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425
JAMA